Lisa Astor | Authors

July 28, 2022

Investigators continue to explore possible systemic treatment options that could improve disease control for patients with brain metastases derived from breast cancer.

July 14, 2022

The use of endocrine therapy as single agents serves as the control arm for many clinical studies seeking to improve upon outcomes with combination regimens and newer agents for patients with HR-positive, HER2-negative advanced breast cancer.

July 13, 2022

Treatment with relacorilant showed improvement in overall survival in patients platinum-resistant or platinum-refractory ovarian cancer when combined with nab-paclitaxel.

June 18, 2022

Several treatment options are being explored for patients who have residual disease or who relapse after CAR T-cell therapy, including a possible second infusion with the same CAR T-cell product.

June 06, 2022

Bevacizumab improved progression-free survival and overall survival when added to frontline chemotherapy in patients with advanced ovarian clear cell carcinoma, according to a retrospective analysis of patients treated in Japan from 2008 to 2018.

June 05, 2022

Improvement in overall survival shown in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab, according to results from the phase 3 PARADIGM trial.